Environment, Social &Governance Report
Year ended 31 December 2023

ESG REPORTYEAR ENDED 31 DECEMBER 2023
1NXERAMay PHARMA
2024 | -Nxera
Pharma1

Nxera Pharma ESG Report 2023
Who We Are

4

About this Report5

Our ESG Approach and Priorities

6

Summary of our 2023 ESG Materiality and KPIs

Message from our CEO

8

Environment

10

Reduction of Emissions and Waste
Strategy Regarding Climate Change

Social - Safety and Quality Assurance

14

Laboratory Animal Care and Alternatives to Animal-Based Biomedical
Research
Core Development-Stage Activities
Supply Chain Transparency and Quality AssuranceMarket Authorization in Asia-PacificSocial - Human Capital Development

18

Promoting Diversity and Pay Equity
Employee Stock OwnershipBenefits and Work-Life Balance
Development Training
Studentship Programs and Academic Sponsorships

Social - Contribution to Society

21

Meeting Unmet Medical Needs
Right to HealthCharity Initiatives

Governance24

Corporate Governance Structure
Operation of Governance Systems
NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

2

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

3

Who We Are

About this Report

Our life’s work, is life itself
Nxera Pharma is a technology-powered biopharmacompany, in pursuit of new specialty medicines toimprove the lives of patients with unmet needs inJapan and globally.
In addition to several products being commercializedin Japan, we are advancing an extensive pipeline ofover 30 active programs from discovery through tolate clinical stage internally and in partnership withleading pharma and biotech companies. This pipeline isfocused on addressing major unmet needs in some of
the fastest-growing areas of medicine across neurology,

GI and immunology, metabolic disorders and rarediseases, and leverages the power of our unique andindustry leading GPCR-targeted structure-based drug
discovery “NxWaveTM” platform to provide a sustainablesource of best- or first-in-class candidates.
Nxera employs over 350 talented people at key
locations in Tokyo and Osaka (Japan), London andCambridge (UK), Basel (Switzerland) and Seoul (South
Korea) and is listed on the Tokyo Stock Exchange(ticker: 4565)

Our Mission
To accelerate the development ofThis 2023 ESG Report provides details on our approachand progress on Environmental, Social and Governance(ESG) initiatives covering the period between 1 January2023 to 31 December 2023.
Our 2023 ESG Report has been prepared by the ESG
Committee, which was established in 2022 with thesupport of our Board of Directors, with the mandate
to manage, lead and oversee our ESG initiatives. The
Chair of our ESG Committee is Miwa Seki, one of our
Independent External Directors, who is renownedfor her ESG expertise and experience in Japan.
Other committee members include Rolf Soderstrom(Independent External Director), Noriaki Nagai(Independent External Director), Chris Cargill (CEO)and Hironoshin Nomura (CFO).

The Company believes that improving our ESG
performance is a vital component for our long-term
growth and success. With this overarching objective,
our ESG Committee will strive to instill our ESG initiatives
across our organization so that environmental, social,and governance goals become the foundations of ourculture, value and business operations.
Our ESG initiatives are priority topics for our Boardof Directors and Executive Officers, and with theleadership of our ESG Committee, our ESG initiatives
are championed and implemented across ourorganization by our Charity Committee, Social
Committee, Environmental and Sustainability Groupand Working Group.

COMMITTEES AND GROUPSOBJECTIVES

Charity Committee

Organize events throughout the year to raise funds for charities
selected through a vote by our employees.

Social Committee

Support increasing employee engagement and boost the success andwell-being of our teams by hosting internal social events.

Environmental andSustainability Group

Implement sustainability practices at our offices and R&D facilities
by building awareness and working actively to find and support
sustainability initiatives.

Working Group

Improve employee engagement by promoting initiatives, such as acompany-wide poster session and social initiatives.

life-changing medicines, by investing in scienceand technology.

Our Vision
To lead the next era of medicine. From Japan, forJapan, and by extension, to the world.

Our Values

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

1

Patients, carers, families, and physicians come
first

2

Innovation and teamwork inspire success3

Focus on top priorities where we can make adifference4

Speed and agility of decision-making

5

Operational excellence

4

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

5

Our ESG Approach and Priorities
At our inaugural ESG Committee meeting in October
2022, Nxera Pharma worked to build our ESG roadmap
and identify potential key priority issues (Materiality)
and corresponding key performance indicators (KPIs).
The Materiality and KPIs identified by the ESG
Committee were approved by our Board of Directors in
March 2023. As Nxera’s ESG long journey roadmap, theMateriality and KPIs set out below are our ESG priority
issues and goals that our organization will strive toMateriality

Environment

1
Promoting environmental
management

2
Diversity, Equity andInclusion (DEI)

Summary of our 2023 ESG
Materiality and KPIs

achieve in the coming years. The objective of our ESG
Committee is to implement these ESG goals across
our organization and to collaborate with both internaland external stakeholders to ensure these priorities
become the foundation of our culture, value andbusiness operations. We recognize that our Materiality
and KPIs are long-term objectives that we hope will
shape our organization’s values and we look forward toreporting progress through annual ESG reports.

Initiatives
Focus on environmental
management systems andenergy reduction timelines
at our UK R&D Facility
to ensure our emissions
and waste levels areappropriately managed

KPIs

Obtain Green Lab
Certification at our UK
R&D Facility within 5 years

Focus on reducing Gender
Gap

Maintain Female Senior
Management Roles(Global) at >30% over the
medium term

Focus on creating R&D
effciencies that will enable
the development of lifechanging medicines forpatients

Promote R&D efficiencies– one preclinicalcompound and one
clinical compound peryear for the next three
years on average from our
in-house pipeline

Enhance and increase
dialogue with ourshareholders

Provide a forum where all
shareholders can join anddiscuss with company
management in an open
and frank manner

1

2

Promoting environmental management

Diversity, Equity and Inclusion (DEI)

In 2023, we’ve focused on improving our laboratory
sustainability practices throughout our R&D facility.
We participated in the My Green Lab program which
evaluates laboratory management and suggests areas
to improve. Both our chemistry and biology laboratories
obtained My Green Lab Certification at Green standard– the highest achievement reflecting a number ofenergy reduction initiatives we’ve introduced. We
are proud to have achieved our Environment KPI byobtaining our certificate ahead of schedule, reflecting
our commitment to ensure the efficient managementof our emissions and waste.

Reducing the Gender Gap at a global level has beena key focus for us. In July 2023, we acquired Idorsia
Pharmaceutical’s Japan, Korea and APAC businesses.
This acquisition resulted in the global percentage offemale employees in senior management roles in 2023
to slightly decrease to 32% compared to 34% in 2022.
However, we have achieved our KPI of maintaining
female senior management roles at over 30% globally
this year and we will continue to focus on improving
against this KPI in 2024.

3

4Social2Creating innovative
pharmaceuticals forpatients

Governance

4Equity and transparency toall stakeholders

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

6

Creating innovative pharmaceuticals forpatients

Equity and transparency to all
stakeholders

During 2023, our in-house pipeline has seen great
progress as we entered two candidates into Phase 1
clinical trials; NXE0048149, a GPR52 agonist for thetreatment of schizophrenia, and NXE0039732, a novel
selective EP4 antagonist being investigated in immunooncology. Although we didn’t progress any new
assets into preclinical development during the year,
our discovery pipeline continues to grow and we areconstantly evaluating exciting targets where we believe
we can develop life-changing medicines for patients.

At our 2023 Annual General Meeting of Shareholders,
we introduced a ‘meet and greet’ session with ourManagement Team to promote an open dialogue andcommunication flow with our shareholders. We believe
the implementation of this forum has, and will continue
to, allow us to successfully achieve our KPI goal ofproviding a setting where our shareholders can join anddiscuss with our company management openly. This
increased shareholder interaction allows for further
engagement with all our stakeholders, and we lookforward to continuing this on an annual basis.

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

7

Message from our CEO
Dear Stakeholders
At Nxera Pharma, we are fully committed to realizing a sustainable future
through supporting breakthroughs in medicine. Through our work, our goal
is to improve the quality of life and health of people around the world. We
practice world-leading science to create life-changing medicines
Following the establishment of our ESG Committee in 2022, we haveworked to assess our organization’s current ESG practices, identify ESG
priorities and action our most important initiatives.
I am pleased to share with you our 2023 ESG Report, which outlines
the efforts made over the past year to make a positive impact on ourenvironmental, social and governance initiatives. We are focused onembedding ESG practices into our business operations and in our culture
and behaviors.
I am very proud of the progress we have made across all four of our
KPIs since the formation of our ESG committee, evident in this report.
However, there is still more to do, particularly as our global organization
has nearly doubled in size in 2023 following the addition of Idorsia
Pharmaceuticals Japan – rebranded to Nxera Pharma Japan (“NPJ”) –and Idorsia Pharmaceuticals Korea – rebranded to Nxera Pharma Korea(“NPK”), bringing a new dimension to our business. This new stage of ourdevelopment motivates us even more to continuing our efforts and driving
forward our ESG initiatives in 2024 and beyond.

Yours sincerely
Chris Cargill
Representative Executive Officer,
President & CEO

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

8

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

9

Environment

Some further notable initiatives are:

Reduction of Emissions and Waste

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

Renewable energy promotion – we continue toconsider environmental awareness when selecting
energy suppliers.

•

Car sharing service – our UK staff at ourCambridge facilities participate in a car-sharing
service.

•

Ecologi® partnership - since 2002, we havepartnered with Ecologi Action Ltd on carbon
reduction projects and tree planting initiatives.
So far, we have contributed to 516.02 tons CO2
reduction ( 315.01 tons reduced through generating
clean electricity from wind power in Mexico, 105
tons reduced through capturing waste biogas
for energy in Turkey, 94.08 tons reduced throughgenerating clean electricity from hydropower inIndia and 1.92 tons reduced through wind power
generation in Bac Lieu Province in Vietnam). We
are proud to have contributed to the plantingof 9335 trees in the mangroves of Marotaola
and Kandrany in Madagascar and Irregele Milato
in Mozambique. Furthermore, we contributed toforest restoration and supporting water securityin Kenya, planting forest gardens in Tanzania andUganda, restoring degraded land in Senegal andsupporting forestation in Gewocha, Ethiopia.

•

Cycle to work – our UK staff can participate in
the UK Government’s Cycle to Work initiative
which provides staff with discounts on new bikepurchases.

•

Energy efficient buildings – our Tokyo
headquarter is located in an energy efficientbuilding with double-glazed windows and individual
air-conditioning systems. We have also installed
LED lighting in our Tokyo office to reduce power
consumption compared to fluorescent lighting.
The nitrogen generation system in the Steinmetz
Building has been improved to reduce energy use.

•

Reduce, Reuse, Recycle - Where items havebeen removed during the work to create newlaboratory areas at our UK R&D facility, these havebeen reused in other parts of the building where
possible or sold for reuse to ensure our waste
levels are as low as possible.

In the UK, we hold an Environment Agency License
for the use and disposal of radioactive materials anda Trade Effluent License, issued by Anglian Water
Services Limited, for the discharge of liquid waste into
the public sewage system. Both licenses stipulate strict
conditions on how we should manage and dispose ofsuch materials and these have been incorporated into
our environmental management systems. Furthermore,
although Nxera Pharma does not hold a HAZWOPER
certification as such certification is not applicablefor the operation of our business, we ensure that ourwaste disposal contractors hold the British Standard

Nxera Pharma is committed to reducing our environmental
impact through our sustainability initiatives and ourenvironmental management systems.
In 2023, Nxera Pharma laboratories secured My GreenLab certification, endorsed by the United Nations’
Race to Zero campaign, recognizing outstanding
laboratory sustainability. Over 70 UK R&D researchers
participated, achieving Green certifications acrossboth our biology and chemistry laboratories, thehighest level of certification. These awards reflect Nxera
Pharma’s dedication to continuously assess, review,and enhance laboratory practices in order to minimize
environmental impact. Prioritizing sustainability, we
actively contribute to global efforts to reduce carbon
emissions and advance a greener future. Our focus
includes clear waste reduction through establishedrecycling protocols and the reduction of single-use•

plastics. We embrace a paperless approach in labs
and offices whenever possible, promoting digital
documentation and communication. Through ongoing
monitoring and improvement, we are committed tomaintaining and enhancing our labs environmental
performance.
In addition, with efficient energy use a core priority
at our offices and R&D facility, our Environmental andSustainability Group members are all My Green Lab
Ambassadors, focused on encouraging our laboratories
to be more sustainable.

CO2 Emissions
from R&D
Facility per
Person2021

Through our focus on environmental management
systems and our energy reduction initiatives, we willcontinue to work on ways to reduce our operationalemissions levels.

3.45
tons
3.54

2022 tons

2021
Electricity Usage
at R&D Facility

2023 3.26
tons

2021
Gas Usage at
R&D Facility

ISO 14001:2015 (Environmental Management) and
BS ISO 50001:2011 (Energy Management, under theframework guidance of PAS99:2012 (Management
System). To ensure compliance of our waste disposal
contractors’ certifications, we take part in our waste
disposal contractors’ annual waste audit process.

1,220,136

2023 1,369,047
kWh1,650,508

2022 kWh

2023 1,749,228
kWh

1,302,095
kWh2022 kWh

1,594,378
kWh

2021
Water Usage at
R&D Facility

1,405
m3
1,990

2022 m3

2023 1,834
m3* Data impacted by site occupancy restrictions due to COVID-19 measures starting March 2020 which introduced working from home measures for staff and lab
operations at 50% capacity. Site occupancy restrictions were not lifted until April 2022, when maximum site occupancy increased to 130 people from 80 people during
periods when highest levels of restrictions were being imposed.

10

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

11

Strategy Regarding Climate Change
The Group conducted a climate change scenario
analysis based on Task Force on Climate-related
Financial Disclosures (TCFD) recommendations to
identify climate change risks and opportunities,
assess financial impact, and consider measures toaddress such an impact. Our scenario analysis referred
to RCP2.6 (below 2°C scenario) and RCP8.5 (4°C
scenario)1,2, adopted by the UN Intergovernmental
Panel on Climate Change (IPCC) as well as the
scenarios used by the International Energy Agency(IEA) and assessed the overall impact to our major

Transition Scenario (1.5˚C)

Physical Scenario (4˚C)
Opportunity

Risk
Accute Event

Chronic Event

Products and services

Increase in frequency andseverity of extreme weather
events such as typhoons,
torrential rains, and floods

Increase in average annual
temperature

Growing demand for medicinesand drug discovery

ImpactImpactThere is a risk of increased
electricity costs due toincreased power usage.

Revenue may increase due toincreased demand for existing
drugs or the development
and commercialization of new
drugs because of changes indisease trends caused by global
warming.

ImpactThere appears to be no areas ofhigh direct physical risk to theGroup’s locations. However, therisk of acute flooding or otherdamage could be significant andaffect the operations of some ofour drug discovery, research anddevelopment, clinical trial, andmarketing operations.
Measures
Formulate business continuity
plans for the head officeand each site to minimize
the damage of a disaster on
operations.

MeasuresThoroughly implement energy
conservation measures at eachsite.

Chronic Event
Water scarcity
ImpactThere is a risk that mid- to longterm water scarcity may resultin interruption of operations due
to water use restrictions.

Opportunity

Risk

global bases in Japan, UK, and South Korea. The resultsof the scenario analysis indicate that the impact ofclimate change on the Group’s business appears to belimited at present, however, the Board of Directors andthe ESG Committee will monitor the progress of themeasures against risks of the entire Group, which havebeen assessed and identified by the analysis. The risks
and opportunities related to climate change for theGroup, their impact on the business, and the Group’s
response are described below.

Policies and Regulations

Resilience

Carbon taxes and CO2 emission regulations

More efficient energy use

ImpactImpact

The introduction of the carbon pricemechanism in Japan, UK, South Korea, Ireland,
US, Switzerland, and other countries where
we have our operational bases may result inincreased regulatory frameworks on energy use
and increased expected energy costs. However,
we expect the impact on our company-wide
operating costs to remain limited.

The promotion of a decarbonized society will leadto the development of new products and services
that improve energy efficiencies.
Measures
Reside in an office building with enhanced ecofriendly features to increase energy efficiency andreduce energy consumption and greenhouse gas(“GHG”) emissions.

MeasuresCalculated GHG emissions for our head officeand each of our sites and analyzed the financial
impact of the carbon price mechanism if it wereintroduced in each of our markets. Started to
examine initiatives to reduce GHG emissions.

With regard to climate change, the Group’s Scope 1 and Scope 2 GHG emissions were 800.66 t-CO23 in FY2023.

Measures
Continue to strengthen ourdevelopment pipeline and seek
opportunities for research anddevelopment of drugs in disease
areas where our pipeline canmake new contributions inrelation to global warming.

Measures
Conduct water resource
acquisition risk studies using
the AQUEDUCT Water Risk
Atlas provided by the World
Resources Institute to determine
the impact on the Group’s
operations.

1

RCP: Representative Concentration Pathways

The RCPs include a stringent mitigation scenario (RCP2.6), two intermediate scenarios (RCP4.5 and RCP6.0) and one scenario with very high GHG emissions (RCP8.5).
Scenarios without additional efforts to constrain emissions (’baseline scenarios’) lead to pathways ranging between RCP6.0 and RCP8.5. RCP2.6 is representative of a
scenario that aims to keep global warming likely below 2°C above pre-industrial temperatures.

2

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

12

3

The Group’s GHG emission reduction targets will be discussed in the future.

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

13SocialLaboratory Animal Care andAlternatives to Animal-Based
Biomedical Research

Safety and Quality Assurance

Nxera Pharma is committed to the humane andresponsible use of animals in biomedical research.
No animal research is conducted in our laboratories
or premises. Instead, we work with experienced andreputable Contract Research Organizations (CROs)
to conduct any necessary research. Our CROs
are selected following careful assessment, and wework only with organizations that conform to thehighest standard of animal care, legal and regulatorycompliance processes, obtained through independent
accreditation procedures and in agreement with ourinternal ethical review processes.
All studies in which animals are used are carefullyplanned and reviewed by our In Vivo Review Forum(IVRF), which comprises a team of scientists andstatisticians before any research starts, in addition to
CRO review by their internal ethical committees. We
abide by the 3R principles of Replacement, Reduction
and Refinement of the use of animals in researchand only commission studies involving the use ofanimals where there are no scientifically appropriate
alternatives. Through our internal review processes, wework to ensure that all experiments are designed to use
the minimum number of animals possible to deliver therequired data and minimize or avoid unnecessary pain,
distress, or discomfort to the animals.
Nxera Pharma is committed to the development and useof scientifically validated alternative testing methods
that are acceptable to regulatory authorities which do
not compromise patient safety or the effectiveness of
our medicines. Accordingly, we have invested heavily inmethods to test effects of candidate drugs on isolated
human cells and in clusters of human cells (organoids),
and in the use of state-of-the-art computationalmodelling to predict the effective concentration of the
drug in the body and biological effects in humans.

Core Development-Stage Activities
Nxera Pharma is passionate about improving thequality of life and health of people around the world
through the discovery and development of effective
and safe medicines. With this core principle inmind, we have developed comprehensive internal
policies and procedures that assure the quality andcompliance of our core development stage activities.
These procedures are revised every two years or more
frequently as required.
Nxera Pharma undertakes clinical trial activities
regulated by Good Clinical Practice (GCP) andis governed by related regulations and guidance
concerned with manufacturing (Good Manufacturing
Practice(GMP),
laboratory
andnon-clinicaltesting (Good Laboratory Practice (GLP) andpharmacovigilance.

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

14

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

Development-stage teams are made up of scientists,
medical and other trained professional staff, supported
by consultants. The team provides scientific andoperational expertise and oversight to facilitate
drug development including Active Pharmaceutical
Ingredient (API) and drug product manufacture, nonclinical study sponsorship, clinical study design, medical
oversight, drug metabolism, pharmacokinetics andexpertise in program management, regulatory affairs
and clinical operations. Therefore, all developmentstage staff are trained in procedures needed to assure
quality compliance of every aspect of clinical trial
conduct. Team members receive training in legislation
and regulation relevant to their role when they join, andperiodic updates thereafter. GMP and GCP training
is delivered annually. Additionally, employees andrelevant consultants are required to be trained in theorganization’s policies and procedures relevant totheir roles.

15

Supply Chain Transparency andQuality Assurance
We have adopted a fabless model that possesses
no manufacturing plant, and for commercialization,
we contract the manufacturing of pharmaceuticals
to contract development and manufacturingorganizations (CDMOs). We select our partners basedon quality standards established in accordancewith our philosophy and policies to ensure a stablesupply of our products. We select our partners basedon comprehensive evaluation criteria that include
Quality & Regulatory, Development, Manufacturing,
Environment, Health & Safety (EHS), ability to promote
projects in partnership, Legal & IP and Finance. We
have developed a process to ensure quality throughrobust collaboration with our business partners,
including procedures to assure quality by reviewing
data and documents provide by these business
partners. These steps include review and approval of
externally generated protocols and reports, review ofcompleted batch manufacturing records for produced
batches, review of analytical method development andvalidation reports, review and approval of certificatesof analysis, ongoing review and monitoring of clinical
trial data while studies are ongoing, and review ofTables Figures and Listings (TFLs).
Furthermore, all suppliers are assessed to ensuresufficient quality management systems are in place
which meet our internal quality assurance procedures

and all relevant regulatory standards. Relevant suppliers
are provided with training by us on procedures tomeet our quality management systems. Regulated
development stage suppliers are expected to comply
with GLP, GMP and GCP as applicable to the activity
being undertaken and to maintain certification from therelevant national authorities. Certificates are collectedduring the assessment and selection of such suppliers
and the suppliers are contractually and legally obliged
to maintain all necessary certifications.

NPJ conducts post-marketing safety control operationsin accordance with the “Ministerial OrdinanceConcerning Standards for Post-Marketing Safety
Control for Pharmaceuticals, Quasi-pharmaceutical
Products, Cosmetics, Medical Devices and Regenerative
Medicine Products” (GVP Ministerial Ordinance).
Under the GVP Ministerial Ordinance, NPJ provides
educational training on pharmaceutical safety control
operations to those who engage in safety control
operations and to the marketing team members basedon annual plans, and introductory educational training
on safety control to all employees at the time they join
the company.

NPJ formulated the Code of Practice for its information
provision activities and conducts information provision
activities in compliance with laws and regulations
based on the Information Provision Procedure Manual.
In addition, NPJ provides all employees who engage
in information provision to healthcare professionals
with the necessary educational training on information
provision activities based on annual plans. In addition,
NPJ monitors its marketing activities by reviewing
monthly reports on what the marketing team has done.

Suppliers undertaking animal experiments are required
to maintain their Association for Assessment andAccreditation of Laboratory Animal Care (AAALAC)
accreditation. The AAALAC International accreditation
program evaluates organizations that use animals
in research, teaching or testing. Those that meet or
exceed AAALAC standards are awarded accreditation.
Where legally permissible Nxera Pharma will at all times
ensure that all relevant information is provided to CROs
to comply with their internal ethical review processes.
Finally, our UK Modern Slavery Statement outlines ourapproach to managing modern slavery risks in our
supply chain. Our 2023 UK Modern Slavery Statement
can be found here.

Marketing Authorization in
Asia-Pacific
Nxera Pharma Japan Co. Ltd. (NPJ; a wholly owned
subsidiary based in Japan) and Nxera Pharma Korea
Co. Ltd. (NPK; a wholly owned subsidiary based inSouth Korea), mainly engage in clinical development
and product commercialization in Japan and South
Korea, respectively, with potential to expand into otherAsia-Pacific (APAC) regions.
In Japan, NPJ successfully launched PIVLAZ™ in April
2022 for the prevention of cerebral vasospasm,
vasospasm-related cerebral infarction, and cerebral
ischemic symptoms after aneurysmal subarachnoid
hemorrhage (aSAH) securing. In South Korea, NPK
received marketing approval of PIVLAZ™ from the
Ministry of Food and Drug Safety (MFDS) in December
2023.

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

NPJ holds our marketing authorization licenses in Japan
from the Ministry of Health, Labor and Welfare (MHLW).
In accordance with the Ministerial Ordinance onStandards for Manufacturing Management and Quality
Control of Pharmaceuticals and Quasi-Drugs (GMP),
NPJ ensures relevant suppliers are provided with
manufacturing and quality control training. In addition,
since August 2021, NPJ have worked to establish
pharmaceutical quality systems (PQS) based on theInternational Conference on Harmonization of TechnicalRequirements for Registration of Pharmaceuticals for
Human Use’s ICH Q10 Pharmaceutical Quality Systems.
Furthermore, NPJ provides educational training onpharmaceutical quality control to those who engage
in quality control operations based annual plans, andintroductory educational training on quality control to
all employees at the time they join the company.
16

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

17

Employee Stock OwnershipSocialHuman Capital Development
Promoting Diversity and Pay Equity
The promotion of diversity and inclusion and thecreation of a collaborative working environment arecore pillars of Nxera Pharma’s vision, as pioneersfrom Japan, to lead the new era of biopharma andmedicine, innovating for both Japanese patients andthe world. As a global company, Nxera Pharma’s Boardof Directors comprise 33% non-Japanese nationals(including our CEO) and 54% of our global workforce
are non-Japanese nationals (Japanese – 46%, British –32%, Rest of the World 22%). We are also proud to havea diverse workforce comprising 46% female colleagues,
including 49% new female hires in 2023.

annually to ensure a consistent and fair approach acrossthe organization for promotions and annual rewards. In
2023, 55 promotions were made, including 34 female
promotions however our global female employees insenior management roles was 32%, down slightly fromto 34% in 2023. In addition, in March 2023, Eiko Tomita
was elected to the Nxera Pharma Board of Directors.
As part of our drive to create an inclusive and informed
culture within our organization, we established adiversity, equity and inclusion council (DEI Council) in
2023. The Council is made up of representatives fromacross the organization, at all levels.

We are committed to pay equality for all colleagues
with our intention to continue to build a diverse andinclusive workforce. Commencing in 2021, a global
review of staff salaries has been conducted on anannual basis against market benchmarks based oneach employee’s role and experience. Our annual Pay
Philosophy is agreed in December and is consistently
applied across the organization based on calibrated
performance rating and position against benchmark
relative to performance.

Nxera Pharma actively forecasts its hiring needs
by determining the required number of full-time
equivalent (FTE) employees needed on each program.
This practice ensures that our programs are wellresourced with people who have the requisite skill sets.
As an organization, we are proud to support skilledworker visa applications for non-British nationals towork at our R&D facility in Cambridge, UK. In 2023, we
supported six skilled worker visa applications.

In December 2021, Nxera Pharma introduced a new
performance calibration process as part of ourworkforce’s performance management framework.
The new process is a business-led forum conducted

Nxera Pharma believes meaningful progress has been
made to promote diversity and pay equity in 2023 andwill continue to make year-on-year progress across theorganization.

Vice President and Above

GenderRepresentation

3

26

3

20

5

23

FEMALEMALE

FEMALEMALE

FEMALEMALE

2021

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

2022

2023

Nxera Pharma actively appoints talented people
with the aim of encouraging them to remain withthe business for the long term. We truly believe that
employees should have a stake in the ownership of
the organization, so they can benefit from their directcontribution to the company. Accordingly, sinceApril 2022, all permanent employees are eligible tobe considered for grants of Restricted Stock Units(RSUs) under Nxera Pharma’s Long-Term Incentive Plan

Benefits and Work-Life Balance
Nxera Pharma runs an active benefits package which
includes salary sacrifice benefits such as Cycle to
Work schemes and pensions. The company also
provides private health insurance, dental, optical,
hearing, complementary therapies to all employees
and subsidized gym memberships for all staff including
placement students.
Nxera Pharma believes in supporting employees who
have young families. The company’s UK family friendly
policies (including maternity, paternity and adoption
leave) were revised in 2022 to provide enhanced
packages to employees compared to the UK statutory
requirements. In 2023, 83% of staff returned to work
after child-care leave, compared to 50% in 2022.
Continued support to families and staff with elderlyfamily members are also provided through childcare
and elderly care support program, which entitles
employees to up to ten days per year of subsidized

Senior Director

00

FEMALE

MALE

2021(LTIP) every year. The participation in and the actual
grants of awards and/or payments to our employees
are made in accordance with the rules of the relevant
LTIP scheme. As of December 2023, 87% of permanent
staff hold RSUs of Nxera Pharma. It is Nxera Pharma’s
intention to continue to award employees further
grants on an annual basis as an additional process ofrecognizing their performance and contributions to theorganization.

childcare and elderly care. In 2023 a total of 94 sessions
were booked by our employees to support working
parents during periods of school closures, child illness
or school holidays. In Japan, a new program was started
in 2023 that allows employees with young families toaccess childcare services free of charge.
Nxera Pharma is committed to supporting employeeswith flexibility in their work schedules while allowing
us to maintain a progressive and productive work
environment. The company has provided a formal
policy to ensure consistency of approach with how
roles can operate flexibly in our working environment.
It balances the need for roles that physically need
to be in the office with those that can have greater
flexibility but still ensuring we maintain presence at oursites to promote collaboration and connectivity acrossthe company.

Associate Director/
Principal Scientist

Director

Senior Scientist II and below

4

3

5

15

11

21

13

14

21

32

13

17

13

17

11

20

75 40

68

36

129 109

FEMALEMALE

FEMALEMALE

FEMALEMALE

FEMALEMALE

FEMALEMALE

FEMALEMALE

FEMALEMALE

FEMALEMALE

FEMALE

FEMALEMALE

FEMALE

2022

2021

2023
18

2022

2023

2021

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

2022

2023

MALE

2021

2022

MALE

2023
19

Development Training

SocialWe are committed to supporting our colleagues
reaching their full potential by providing opportunities
for growth and development, and through rewarding
performance and leadership. Nxera Pharma ensuresthat each employee has the requisite and up-to-dateskills training for their role, facilitated through regularpersonal development discussions and tailored training
programs based on our training matrix. The company
also supports individuals attaining further qualifications
or certifications within their field of expertise. We
are committed to scientific talent development
through internal secondments and regular conference
attendance.

over
45 hours
100%

Tailored Training Program for each
employee based on training matrix

18 hours
5%

Inspiring Leadership
Program

In addition to fostering an environment to encourage
our employees to develop as leaders, Nxera Pharma
has a formal performance management framework
which includes objective setting for every employee inthe company and bi-annual performance appraisals.
Performance calibration meetings at the end of theyear are conducted with senior leaders of each team
to discuss the performance of every employee. Thesemeetings also include discussions on promotions andthe near-term development pathway as part of thedevelopment plans for each individual.
Finally, Nxera Pharma utilizes a specialized third-party

Contribution to Society

In 2022, we began a new leadership strategy byintroducing formal management training for all line
managers in addition to the tailored training programs.
There are three programs targeted at different levels
and experience of line managers. New managers
or soon-to-become managers are enrolled in theManagement Foundation Program and managers who
have had a few years’ experience are enrolled in theManagement Development Program. Managers who are
at Director-level or above are enrolled in the Inspiring
Leadership Program. These three programs are rolled
out on an annual basis and new participants areenrolled as they become promoted, are newly hired
into the business, or are flagged as potential managers
in the near term.

30 hours
10%

Meeting Unmet Medical Needs

8 hours11%

Our proprietary GPCR-targeted structure-based drug
discovery NxWave™ platform has enabled us to develop
small molecules, peptides and antigens for antibody
discovery. To date, we have leveraged our technologies
and expertise to create a pipeline of drug candidates
targeting GPCRs that we believe have potential to
become first-in-class or best-in-class medicines intherapeutic areas such as neurology, immunology andgastroenterology diseases.

Our lead product PIVLAZ® (clazosentan) is alreadycommercially available in Japan for the preventionof cerebral vasospasm, vasospasm-related cerebral
infarction, and cerebral ischemic symptoms after
aneurysmal subarachnoid hemorrhage (aSAH) andfollowing a successful launch in April 2022. Anotherexciting candidate, Daridorexant, was filed in Japan for
insomnia in October 2023 and is already marketed in
US/Europe as QUVIVIQ®.

Alongside our in-house programs, we are collaboratingwith world-leading partners, including majorbiopharmaceutical companies, emerging technology
companies and innovative venture capital funds toaddress diseases with high unmet medical needs, andfor which there are no suitable treatments currently
available.

The NPJ and NPK team joining Nxera Pharma broughtsignificant experience in drug development andcommercialization with a strong footprint in Japan.
The enlarged Japan team also provides a platform toexpand commercial operations beyond Japan to other
APAC markets and extend the regional product range
over time, which should lead to delivering more drugs
to patients in the region.

Nxera Pharma gained Japan and Asia-Pacific (ex-China)
territory rights to an exciting pipeline of medicinesfrom Idorsia’s portfolio in July 2023 in the context
of its acquisition of IPJ and IPK (now NPJ and NPK).
Management
Development Program

Management
Foundation
Programonline platform to deliver an employment engagement
survey annually to measure the connection employees
have towards their work, team and company, andexamine the factors that influence it. We aim to use thesurvey results to guide us with further developing ways
to increase employee satisfaction and development
strategies. In 2023, our employee survey response
rate was 91% globally, with the overall split of responses
being 64% positive, 29% neutral and 7% negative. Thisis an increase from 2022 where we saw 60% positive
responses. We have developed action plans to focus
on improvement areas throughout 2024, with a focus
on action plans by department.

Dementia

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

Neurological Disorders

Immunological Disorders

Other

INDICATION

INDICATION

INDICATION

Schizophrenia

Substance use
disorders

Narcolepsy

Cancer~55
million~24
million~350
millionIBD~3million~18
millionOUR CANDIDATES

the world on such sponsorship arrangements.

M1 agonist

In addition, Nxera Pharma supports industrial
placement student programs in conjunction with UK
universities. This is an annual program designed toprovide students with practical experience within theirdesignated field of expertise. In 2023, Nxera Pharma
welcomed ten industrial placement students to work
alongside our scientists on 12-month placements.

20

M1/M4 agonist

mGlu5 NAM

~7

millionOX2 agonist

GPR52 agonist

EP4 antagonist

Type 2 Diabetes/ Obesity

Anorexia

NUMBER OF PATIENTS*~200
millionOUR CANDIDATES

M4 agonist
M1/M4 agonist

AtopicDermatitis

NUMBER OF PATIENTS*

NUMBER OF PATIENTS*

Studentship Programs and Academic Sponsorships
Nxera Pharma supports world-leading academic
institutions and their students through various
research, studentship and sponsorship arrangements.
Such programs are designed to help post-graduate
students and academics work on collaborative
research programs in line with their higher education
requirements. In some circumstances, Nxera Pharma
supports such students and academics on writing their
theses and publication of their findings. In 2023, Nxera
Pharma worked with 19 academic institutions aroundWe are dedicated to developing life-changing
medicines for the many millions of patients with these
diseases around the world.

~460
million~70
millionOUR CANDIDATES

CCR6antagonist

H4 antagonist

GPR35 agonist

PAR2 mAb

GLP1 agonist

MC4 antagonist

EP4 agonist* Source of Number of Patients: World Health Organization, Evaluate Pharma, The European Federation of Crohn‘s & Ulcerative Colitis Associations (EFCCA), Narcolepsy
Network, Inc., GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (October 2016). “Global, regional, and national incidence, prevalence, and years lived
with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015”. Lancet. 388 (10053): 1545–1602. Cancer
Research UK worldwide incidence of new cases of cancer per year. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of
inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease. Lancet Gastroenterol Hepatol. 2020;5(1):1730. doi:10.1016/S2468-1253(19)30333-4. British Journal of Dermatology, Volume 190, Issue 1, January 2024, Pages 55–61, https://doi.org/10.1093/bjd/ljad339. https://www.
singlecare.com/blog/news/eating-disorder-statistics/
NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

21

Right to Health
Nxera Pharma takes its responsibility to work towards
providing access to medicines and healthcare to
all people around the world seriously. The company
provides access to some of its scientific discoveries
in order that others may use them for their own
research to improve the understanding of diseases
and accelerate the development of new medicines.
For example, our scientists have solved over 390 GPCR
structures from more than 50 different GCPR targets
using our innovative GPCR-targeted structure-based
drug discovery NxWave™ platform, with many of these
released into the scientific community.
In April 2024, Nxera Pharma joined the World Orphan
Drug Alliance (WODA), a global alliance of commercial

distributors dedicated to providing access totreatments for rare diseases and specialty medicines
in complex markets around the world. The Allianceconsists of 13 member companies and provides
access to approximately 200 million rare disease
patients across 154 countries. Nxera Pharma will
represent WODA in Japan and South Korea. Throughthe Alliance and its global networks, Nxera Pharma
will gain access to a pipeline of novel medicines
targeting rare or orphan diseases as potential licensing
opportunities (with no obligation) for its late clinicalstage and commercialization operations in Japan andSouth Korea. Economic terms would be determined on
an individual basis should Nxera Pharma decide to inlicense any product opportunities from the WODA.

Charity Initiatives
Nxera Pharma actively seeks to contribute to the development and enhancement of our communities as well as tothe broader society. In 2023, we made charitable donations amounting to £16,891.62 to the following organisations
and initiatives:

2023 Donations£4,374£4,999

St Nicholas Hospice

Ecologi Action Ltd.99£3,000£500

DEC Turkey / Syria
Earthquake

Alzheimers Research UK In2Science UK£4,017.63

Our Charity Committee raised £4017.63 for In2Science through various initiatives such as running a step challenge,
quiz evening, bake-offs and a Christmas raffle. Nxera Pharma agreed to match the fundraised amount raised by
the Charity Committee which brought the total amount donated to In2Science to £8035.26. In2Science UK isa charity that provides young people from low-income and disadvantaged backgrounds an opportunity to gain
practical insight into the STEM sector as well as knowledge and confidence to progress to university.
In 2024, the Charity Committee will be raising money for EACH, a UK charity that provides support for families
and care for children and young people with life-threatening conditions across Cambridgeshire, Essex, Norfolk
and Suffolk, UK.

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

22

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

23

Governance

We have adopted a governance structure comprising
the Nomination Committee, Audit Committee andCompensation Committee as stipulated by the Companies
Act of Japan in order to strengthen our Board of Directors’
oversight, increase transparency and speed up thedecision-making of management, among other reasons.
Under this structure, we have separated the oversightfunction and business execution function of management
and have largely delegated business decision-making
authorities to our Executive Officers. We believe thisstructure supports our focus to increase management
oversight and efficiencies and our governance principles

Corporate Governance Structure

Dr. Shinichi Tamura
Chairman of the Board

Dr. David Roblin
External Independent Director

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

Mrs. Eiko Tomita
External Independent Director

Our Scientific Advisory Board consists of leading scientificexperts from the pharmaceutical industry and academia,
who ensures management decisions are based on scientificexpertise. Our significant investment decisions are madeby our Board of Directors based on recommendations
made by our Investment Committee. Lastly, our ESG
Committee was formed in 2022 with the mandate to makerecommendations to our Board of Directors and oversee
our overall ESG strategy, policies and practices.

Mr. Tomohiro Tohyama
External Independent Director

Mr. Rolf Soderstrom
External Independent Director

Mr. Kuniaki Kaga
External Independent Director

Mr. Noriaki Nagai
External Independent Director

Ms. Miwa Seki
External Independent Director

LEADERSHIP GROUPSAND COMMITTEESDESCRIPTION AS OF 31 DECEMBER 2023

Board of Directors
and Executive
Offices

Our Articles of Incorporation stipulate that there may be no more than ten
directors. Our Board of Directors comprises nine directors (two internal
directors and seven independent external directors). Our Board of Directors
sets basic management policies, supervises the execution of duties by our
Executive Officers and directors, and deliberates on management strategies torealize sustainable growth and add corporate value. One of the directors servesconcurrently as our representative executive officer (CEO).
We currently have eight Executive Officers, including our CEO, who have been
mandated by the Board of Directors with business execution authorities.

With our vision as pioneers from Japan to lead the new eraof biopharma and medicine, innovating for both Japanesepatients and the world, we recognize that building aneffective system of corporate governance is an importantmanagement priority to enhance corporate value over the
medium to long term.
We have therefore continued to strengthen ourgovernance structure and management systemthrough the appointment of independent external
directors and the establishment of cooperation
between the Audit Committee, the external auditor andthe Internal Audit Department to support the strategic
management and oversight functions of our Board of

Mr. Chris Cargill
Representative Executive Officer,
President and Chief Executive Officer

are set out in our Corporate Governance Guidelines.

We have seven independent external directors. There are no personal, capital,or transactional relationships or other special interests that may affect theirimpartiality and objective decision-making between the independent external
directors and Nxera Pharma.

Directors. At the same time, we have strived to increase
the integrity and transparency of our management
governance structure by maintaining accountability
to and communication with all stakeholders, including
shareholders, employees, business partners, customers,
creditors, consumers and local communities.

24

Independent
External Directors

In electing our independent external directors, we recognize the importanceof ensuring the effectiveness of corporate governance and ensure adequate
impartiality to execute their duties as an independent external director. Basedon their career histories and relationships to Nxera Pharma, we have determinedthat each independent external director can ensure adequate impartiality to
execute their duties as an independent external director.

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

25

Nomination Committee

Operation of Governance Systems

Our Nomination Committee comprises our Chairman of the Boardand three independent external directors. The Committee assesses
whether candidates have sufficient expertise and experience to support
our global strategy and puts nominations forward to our shareholders
for such candidates to be elected as directors. Furthermore, theNomination Committee makes candidate recommendations to the Boardof Directors for the appointment of executive officers.

Compensation Committee

Our Compensation Committee comprises three independent external
directors, one of whom is the Chair of the Committee, our CEO and ourChairman of the Board. The Committee sets the remuneration policy fordirectors and Executive Officers, and based on that policy determines
their individual remuneration in view of performance and othercontributions to Nxera Pharma.

Audit Committee

Our Audit Committee comprises five independent external directors.
The Audit Committee works closely with the Internal Audit Department
and is responsible for auditing finance and internal control processes,
overseeing the execution of duties of directors and executive officers, aswell as the appointment and dismissal of external auditors.

Investment Committee

Our Investment Committee comprises our CEO, Chairman of theBoard, three independent external directors and five Executive Officers.
The Investment Committee evaluates prospective investment anddivestment projects and makes investment recommendations to theBoard of Directors.

R&D Committee

Our R&D Committee comprises our CEO, three independent external
directors and two Executive Officers. The R&D Committee promotes
an open, transparent and respectful cross-border working culture, andsupports best practice knowledge sharing regarding innovation and R&D.

ESG Committee

Our ESG Committee comprises our CEO, four independent external
directors and three Executive Officers. The ESG Committee wasestablished in 2022 with the mandate to make recommendations to theBoard of Directors and oversee our overall ESG strategy, policies andpractices.

Scientific Advisory Board

Our Scientific Advisory Board consists of a total of 11 world-leading
experts, including one independent external director. The SAB provides
valuable insight and perspective relevant to drug discovery, development
and strategic areas of focus for Nxera Pharma.

We are committed to conducting our business with integrity and our governance systems ensure that appropriate
operational structures are in place. A summary of our governance systems is as follows:
GOVERNANCE SYSTEMSDESCRIPTION
Nxera Pharma is overseen by the Board of Directors, committed toensuring ethical business practices across our business and acting asa responsible member of society in all our business endeavors. Our
principles of corporate behavior are instilled throughout the organization
through our Code of Conduct. Mandatory training covering relevantlaws, regulations and policies, as well as compliance awareness including
corruption (e.g., bribery and anti-corruption) are provided to our staff andcompliance with training requirements are monitored on an ongoing basis.

Anti-Corruption Measures

We strive to undertake our business fairly with honesty and transparency
and therefore are committed to maintaining the highest possible
standards of business practice. Consequently, in accordance with our
Anti-Bribery and Corruption Policy, Nxera Pharma observes and upholds
a zero-tolerance approach to acts of bribery and corruption. We do nottolerate fraud, corruption or abuse of position for personal gain by any
member of staff or any other person associated with us. Accordingly,
through our Anti-Fraud and Anti-Facilitation of Tax Evasion Policies, wehave established mechanisms to minimize the risk of fraud and criminal
facilitation of tax evasion.

Supply Chain Due Diligence
Business Ethics andCompliance Systems

Along with our Supply Chain Transparency and Quality Assurance
measures, we undertake due diligence when considering taking on new
suppliers and continuously review our existing suppliers. All our suppliers
undergo a supplier approval process that includes risk assessments basedon qualitative and economic factors to identify any indicators of supply
chain risks. Such risk assessment includes checks against association with“anti-social forces” (hanshakaiteki seiryoku) and organized crime groups.
In addition, to make or receive payments from counterparties who havepassed prescribed screening processes, we require such payments to bemade through wire-transfers or remittances via bank accounts which areverified by our Finance department. In addition, since the war in Ukraine
began in February 2022, we have taken measures to ensure that we do nottrade directly with any Russian suppliers and do not breach any internalsanctions.
We require all our contracting partners, suppliers and other third parties tooperate in line with internationally recognized legal, regulatory and humanrights frameworks. We are committed to ensuring that we identify andeliminate to the fullest extent possible all potential modern slavery risks
related to our business. We do not tolerate forced labor either within ourbusiness itself or within our supply chain. For further details of our actions
to prevent modern slavery in our business dealings, please refer to our2023 Modern Slavery Statement.
As at the date of this 2023 ESG Report, we currently are not aware of
any areas that would be considered high risk and we are not aware of any
third-party company and/or supplier activity that may contravene our
ethical business practices.
Continues overleaf

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

26

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

27

Whistleblowing Policy

Internal Controls

Our Whistleblowing Policy encourages staff and external stakeholders
to raise any concerns that they may have about our conduct or theway in which our business operates. All our staff have a duty to reportany concerns they may have about potential breaches of our Code of
Conduct, the laws and regulations of the countries we operate in, or
our policies, procedures and guidelines. Our policy outlines our internalmechanism for reporting, investigating, and remedying any wrongdoingin the workplace and encourage individuals to raise their concerns andany grievances internally in the first instance. Along with our internal
whistleblowing mechanism, we have external whistleblowing hotline
services that can be used by both internal and external stakeholders.
The external independent whistleblowing service and confidential
reporting service, which allow staff and external stakeholders to raise
any issues or concerns in complete confidence and if they wish, on an
anonymous basis. Our policy ensures the safety of whistleblowers fromany damage and retaliation because of making the reporting.
Document Management
SystemDocument management rules and policies ensure strict controls for the
management and storing of documents.

Risk Management System

Decision making by our Board of Directors are made based on
discussions and deliberations considering, where relevant, opinions
of external experts. Responsible executive officers and senor staffs
analyze and make the status of risks and mitigation measures taken on aquarterly basis to the Audit Committee and Board of Directors. Further,based on internal audit findings, our Internal Audit Department also
provides guidance and recommendations on risk management systems
to our Board of Directors.

Job Execution System

Authority of officers and employees are defined and managed inaccordance with our governance policies. To ensure operations
are conducted efficiently and appropriately, subsidiaries havebeen delegated authorities with structured governance reporting
responsibilities to Nxera Pharma and our Board of Directors.

Internal Controls Systems•

Evaluate the design and operation of internal controls over financial
reporting every year to ensure effectiveness according to theguidelines of the Financial Services Agency (J-SOX).

•

Prepare an annual Internal Control Report pursuant to the Financial
Instruments and Exchange Act.

Independence and Objectivity•

The Head of Internal Audit Department reports administratively
to the CEO and functionally to the Audit Committee, and also
reports directly to the Board of Directors, thus maintaining
independence and objectivity. In this way, the Board of Directors
oversees the compliance with relevant laws and regulations in theabovementioned areas.

The Internal Audit Department has meetings with both the CEO and the
Audit Committee on a frequent basis to share information and provide
updates on risks and controls.

Data Protection & Privacy
Systems

We consider the protection of personal data and privacy a vital partof our governance structure. We have implemented a comprehensive
global data protection framework along with General Data Protection
Regulation (GDPR) policies to comply with both the EU and UK GDPR in
addition to personal information management regulations in Japan. The
handling and monitoring of EU and UK personal data is managed by ourPrivacy Team comprising members from key departments including
Legal, Information Technology, HR and Investor Relations and our Privacy
Lead is our Chief Accounting Officer. We have appointed Hamish Corner,
Privacy Partner at Shoosmiths LLP, as our external Data Protection
Officer.

Our Internal Audit Department continuously evaluates the designand operation of internal controls to comply with relevant laws andregulations. Our Internal Audit Department conducts internal audits
across all the Group companies on a three-year rotation with the aimof maintaining and strengthening our internal controls whilst ensuring
appropriate and effective business operations. The scope of our internal
audit includes areas such as policies and procedures, organizational
structure, procurement, IT security and compliance awareness.
Specifically, the activities of the Internal Audit Department include:

Assurance and Recommendations•

Decide audit themes on a risk-based approach, execute internal
audits, and report the results to the CEO and the Audit Committee.

•

Issue audit recommendations for remediation and support theaudited units to develop action plans.

•Continue to work together with the audited units and follow up on
the remediation actions.

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

28

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 202329

www.nxera.life

TOKYO, JAPANSEOUL, SOUTH KOREA

Group Headquarters

Corporate Office

Midtown East
9-7-2 Akasaka Minato-ku
Tokyo 107-0052
Japan

F17, 410 Teheran-Ro
GangNam-Gu
Seoul 06192
South Korea

CAMBRIDGE, UNITED KINGDOMLONDON, UNITED KINGDOMBASEL, SWITZERLAND

R&D Facilities

Corporate Office

Corporate Office

Steinmetz & Cori Buildings
Granta Park, Great Abington
Cambridge CB21 6DG
United Kingdom

First Floor, Burleigh on the Strand
355-359 Strand
London WC2R 0HS
United Kingdom

Office 1901, Spaces Grosspeter Tower
Grosspeteranlage 294052 Basel
Switzerland

NXERA PHARMA - ESG REPORT YEAR ENDED 31 DECEMBER 2023

30